For advanced NSCLC, platinum-based doublet chemotherapy remains the standard first-line chemotherapy, especially in tumors not harboring either epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation2. Here, ALK is linked to non-small cell lung carcinoma.